Australia's prime minister said Sunday he was ready to "engage" with billionaire X owner Elon Musk over his criticism of the government's ban on under-16s joining social media. Anthony Albanese hailed the parliament's Thursday passage of landmark legislation requiring social media firms to take "reasonable steps" to prevent young teens from having accounts. The law, which will come into effect after 12 months, gives few details of how it will be enforced, including how sites like Facebook, Instagram and X will verify users' ages. Musk -- who has been named Donald Trump's government efficiency chief in the incoming US administration -- posted on X last month that the law "seems like a backdoor way to control access to the Internet by all Australians". "We will talk to anyone," Albanese said when asked if he would discuss the legislation with Musk. "With regard to Elon Musk, he has an agenda. He's entitled to push that as the owner of X, formerly known as Twitter," Albanese told Australian public broadcaster ABC. When the interviewer mentioned that Musk was also Trump's "right-hand man", the prime minister replied: "We will engage, we will engage." Social media firms that fail to comply with the new law face fines of up to Aus$50 million (US$32.5 million) for "systemic breaches". Musk's platform in October lost a legal bid to avoid a US$417,000 fine levelled by Australia's online watchdog, which has accused X of failing to stamp out harmful posts. The government will decide over the next 12 months how to implement the ban, Albanese said, insisting, however, that it would not require people to provide identification. "The obligation will be on social media companies to do everything they can to make sure that those people under 16 don't have access to social media," the prime minister said. "We know that social media companies have more information about you and I than some of our friends do," he added. "We know that they are able to do that, and the obligation will be on them." Albanese said he was "determined" to implement the legislation. "I've met parents who have had to bury their children as a result of the impact that social media has had as a result of bullying, and we need to do something about it," he said. Several social media giants have promised to work with the government on implementing the law. But they have also criticised the legislation, saying it was "rushed", full of unanswered questions, and did not take into account the views of experts who opposed it. The UN children's charity UNICEF Australia warned this week that the law was no "silver bullet" against online harm and could push kids into "covert and unregulated" spaces online. djw/mp/cwl Get any of our free email newsletters — news headlines, sports, arts & entertainment, state legislature, CFD news, and more.Flames prospect Zayne Parekh looking to keep Canadian world junior dream alive
REVIVER® HELPS DRIVE THE SPIRIT OF GIVING THIS HOLIDAY SEASON
How the stock market defied expectations again this year, by the numbersAMESBURY, Mass. , Dec. 2, 2024 /PRNewswire/ -- Provident Bancorp, Inc. (the "Company") (Nasdaq:PVBC), the holding company for BankProv (the "Bank"), today announced that its Board of Directors has adopted a new stock repurchase program. Under the repurchase program, the Company may repurchase up to 883,366 shares of its common stock, or approximately five percent of the current outstanding shares. The repurchase program was adopted following the receipt of non-objection from the Federal Reserve Bank of Boston . The repurchase program permits shares to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission. Repurchases will be made at management's discretion at prices management considers to be attractive and in the best interests of both the Company and its stockholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company's financial performance. Open market purchases will be conducted in accordance with the limitations set forth in Rule 10b -18 of the Securities and Exchange Commission and other applicable legal requirements. The repurchase program may be suspended, terminated or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate the Company to purchase any particular number of shares. About Provident Bancorp, Inc. Provident Bancorp, Inc. (NASDAQ:PVBC) is the holding company for BankProv, a full-service commercial bank headquartered in Massachusetts . With retail branches in the Seacoast Region of Northeastern Massachusetts and New Hampshire , as well as commercial banking offices in the Manchester / Concord market in Central New Hampshire , BankProv delivers a unique combination of traditional banking services and innovative financial solutions to its markets. Founded in Amesbury, Massachusetts in 1828, BankProv holds the honor of being the 10th oldest bank in the nation. The Bank insures 100% of deposits through a combination of insurance provided by the Federal Deposit Insurance Corporation (FDIC) and the Depositors Insurance Fund (DIF). For more information, visit bankprov.com . Forward-Looking Statements This news release may contain certain forward-looking statements, such as statements of the Company's or the Bank's plans, objectives, expectations, estimates and intentions. Forward-looking statements may be identified by the use of words such as, "expects," "subject," "believe," "will," "intends," "may," "will be" or "would." These statements are subject to change based on various important factors (some of which are beyond the Company's or the Bank's control), and actual results may differ materially. Accordingly, readers should not place undue reliance on any forward-looking statements (which reflect management's analysis of factors only as of the date on which they are given). These factors include: general economic conditions; interest rates; inflation; levels of unemployment; legislative, regulatory and accounting changes; monetary and fiscal policies of the U.S. Government, including policies of the U.S. Treasury and the Board of Governors of the Federal Reserve Bank; deposit flows; our ability to access cost-effective funding; changes in liquidity, including the size and composition of our deposit portfolio and the percentage of uninsured deposits in the portfolio; changes in consumer spending, borrowing and savings habits; competition; our ability to successfully shift the balance sheet to that of a traditional community bank; real estate values in the market area; loan demand; the adequacy of our level and methodology for calculating our allowance for credit losses; changes in the quality of our loan and securities portfolios; the ability of our borrowers to repay their loans; our ability to retain key employees; failures or breaches of our IT systems, including cyberattacks; the failure to maintain current technologies; the ability of the Company or the Bank to effectively manage its growth; global and national war and terrorism; the impact of the COVID-19 pandemic or any other pandemic on our operations and financial results and those of our customers; and results of regulatory examinations, among other factors. The foregoing list of important factors is not exclusive. Readers should carefully review the risk factors described in other documents that the Company files from time to time with the Securities and Exchange Commission, including Annual and Quarterly Reports on Forms 10-K and 10-Q, and Current Reports on Form 8-K. Investor contact: Joseph Reilly President and Chief Executive Officer Provident Bancorp, Inc. jreilly@bankprov.com View original content to download multimedia: https://www.prnewswire.com/news-releases/provident-bancorp-inc-adopts-stock-repurchase-program-302320082.html SOURCE Provident Bancorp, Inc.NEW YORK — The man charged with killing UnitedHealthcare CEO Brian Thompson was not a client of the medical insurer and may have targeted it because of its size and influence, a senior police official said Thursday. NYPD Chief of Detectives Joseph Kenny told NBC New York in an interview Thursday that investigators have uncovered evidence that Luigi Mangione had prior knowledge UnitedHealthcare was holding its annual investor conference in New York City. Mangione also mentioned the company in a note found in his possession when he was detained by police in Pennsylvania. Suspect Luigi Mangione is taken into the Blair County Courthouse on Tuesday in Hollidaysburg, Pa. "We have no indication that he was ever a client of United Healthcare, but he does make mention that it is the fifth largest corporation in America, which would make it the largest healthcare organization in America. So that's possibly why he targeted that company," Kenny said. People are also reading... UnitedHealthcare is in the top 20 largest U.S. companies by market capitalization but is not the fifth largest. It is the largest U.S. health insurer. Mangione remains jailed without bail in Pennsylvania, where he was arrested Monday after being spotted at a McDonald's in the city of Altoona, about 230 miles west of New York City. His lawyer there, Thomas Dickey, said Mangione intends to plead not guilty. Dickey also said he had yet to see evidence decisively linking his client to the crime. Mangione's arrest came five days after the caught-on-camera killing of Thompson outside a Manhattan hotel. Luigi Mangione, a 26-year-old Ivy League graduate, was arrested on December 9, 2024, after a six-day manhunt and charged with the murder of UnitedHealthcare CEO Brian Thompson. His arrest has sparked a viral social media movement, with many hailing him as a symbol of resistance against systemic healthcare failures. The #FreeLuigi movement gained significant traction, with his social media profiles amassing over 100,000 new followers before being suspended. Despite this, the movement continues to trend, highlighting public discontent with the U.S. healthcare system. Some social media users argue that Mangione's radicalization stemmed from the struggles faced by millions in obtaining necessary healthcare, and not from his university education. Mangione’s arrest at a McDonald's in Altoona led to the seizure of a "ghost gun," a suppressor, fake IDs, and a manifesto criticizing the healthcare system. While the manifesto seems to admit guilt, some users question Mangione's responsibility, pointing out discrepancies in surveillance photos. The fascination with Mangione has only intensified, with discussions about his attractiveness and comparisons to characters in Ryan Murphy's productions. The phenomenon is reminiscent of society's long-standing obsession with infamous criminals, blurring lines between horror and hero worship. Former FBI agent Rob D’Amico noted that Mangione is seen by some as a "Robin Hood" figure fighting against corporate greed, which complicates the investigation. Police say the shooter waited outside the hotel, where the health insurer was holding its investor conference, early Dec. 4. He approached Thompson from behind and shot him before fleeing on a bicycle through Central Park. Mangione is fighting attempts to extradite him back to New York so that he can face a murder charge in Thompson's killing. A hearing was scheduled for Dec. 30. The 26-year-old, who police say was found with a " ghost gun " matching shell casings found at the site of the shooting, is charged in Pennsylvania with possession of an unlicensed firearm, forgery and providing false identification to police. Luigi Mangione was arrested Monday in Altoona, Pennsylvania, in connection with the killing of UnitedHealthcare CEO Brian Thompson in what law enforcement has called a "targeted attack." Mangione is from a prominent Maryland family with extensive business interests. The Mangione family is known for developing real estate and running businesses. Relatives expressed shock over the arrest and offered condolences to Thompson’s family. Mangione faces multiple charges, including murder, firearm possession, and forgery, in New York and Pennsylvania. Mangione is an Ivy League graduate from a prominent Maryland real estate family. In posts on social media, Mangione wrote about experiencing severe chronic back pain before undergoing a spinal fusion surgery in 2023. Afterward, he posted that the operation was a success and that his pain improved and mobility returned. He urged others to consider the same type of surgery. On Wednesday, police said investigators are looking at his writings about his health problems and his criticism of corporate America and the U.S. health care system. Kenny said in the NBC interview that Mangione's family reported him missing to San Francisco authorities in November. Get the latest in local public safety news with this weekly email.
Wiikwemkoong Unceded Territories has taken a significant step toward energy sustainability with the launch of a groundbreaking Electric Vehicle (EV) infrastructure project. Approved by Wiikwemkoong Leadership, this initiative combines cutting-edge technology and renewable energy to benefit the community and environment. In collaboration with Vortex Technology Group and supported by key funding programs, the project includes the installation of Level 2 and Level 3 EV chargers alongside a revolutionary Battery Energy Storage Solution (BESS) at the community’s Recreational Complex. The launch event on November 27, 2024, was celebrated by Ogimaah Ominika and Vortex CEO Brian Walters. Ogimaah Ominika remarked, “When private sector companies partner and invest with Indigenous communities, the outcomes benefit technology, the environment, and the people.” The Vortex BESS technology, central to this initiative, offers unique advantages over traditional lithium-ion systems. Utilizing graphene-based, solid-state cells, the batteries are safer, longer-lasting, and faster-charging. They integrate seamlessly with the complex’s rooftop solar array, enabling EV charging and critical power supplies even during outages. This innovative design reflects Wiikwemkoong’s commitment to green energy and resilience. The project has been made possible through partnerships and funding from the IESO Indigenous Energy Support Program (IESP), NRCAN’s ZEVIP program, and in-kind contributions from Vortex. The IESP has supported over 170 Indigenous communities with $74 million since its inception, funding initiatives in renewable energy, storage systems, and microgrid development.The program underscores the role of Indigenous leadership in driving Ontario’s energy transition. Brian Walters highlighted, “This installation showcases how our technology can enhance EV charging and emergency power systems, reinforcing Wiikwemkoong’s leadership in sustainable innovation.” The project is more than infrastructure—it’s a vision for the future. The 24/7 accessible chargers will attract visitors to explore Wiikwemkoong’s cultural and ecological offerings while supporting a shift to cleaner transportation. By commissioning the chargers in mid-2025, the community will further its goals of environmental stewardship and energy independence. Wiikwemkoong’s initiative sets a national example, blending green innovation with cultural leadership to create lasting benefits for its people and the planet. -30- No media for this story
NEW YORK — The man charged with killing UnitedHealthcare CEO Brian Thompson was not a client of the medical insurer and may have targeted it because of its size and influence, a senior police official said Thursday. NYPD Chief of Detectives Joseph Kenny told NBC New York in an interview Thursday that investigators have uncovered evidence that Luigi Mangione had prior knowledge UnitedHealthcare was holding its annual investor conference in New York City. Mangione also mentioned the company in a note found in his possession when he was detained by police in Pennsylvania. "We have no indication that he was ever a client of United Healthcare, but he does make mention that it is the fifth largest corporation in America, which would make it the largest healthcare organization in America. So that's possibly why he targeted that company," Kenny said. UnitedHealthcare is in the top 20 largest U.S. companies by market capitalization but is not the fifth largest. It is the largest U.S. health insurer. Mangione remains jailed without bail in Pennsylvania, where he was arrested Monday after being spotted at a McDonald's in the city of Altoona, about 230 miles west of New York City. His lawyer there, Thomas Dickey, said Mangione intends to plead not guilty. Dickey also said he had yet to see evidence decisively linking his client to the crime. Mangione's arrest came five days after the caught-on-camera killing of Thompson outside a Manhattan hotel. Police say the shooter waited outside the hotel, where the health insurer was holding its investor conference, early Dec. 4. He approached Thompson from behind and shot him before fleeing on a bicycle through Central Park. Mangione is fighting attempts to extradite him back to New York so that he can face a murder charge in Thompson's killing. A hearing was scheduled for Dec. 30. The 26-year-old, who police say was found with a " ghost gun " matching shell casings found at the site of the shooting, is charged in Pennsylvania with possession of an unlicensed firearm, forgery and providing false identification to police. Mangione is an Ivy League graduate from a prominent Maryland real estate family. In posts on social media, Mangione wrote about experiencing severe chronic back pain before undergoing a spinal fusion surgery in 2023. Afterward, he posted that the operation was a success and that his pain improved and mobility returned. He urged others to consider the same type of surgery. On Wednesday, police said investigators are looking at his writings about his health problems and his criticism of corporate America and the U.S. health care system. Kenny said in the NBC interview that Mangione's family reported him missing to San Francisco authorities in November.
Forge Institute Launches Phoenix Xcelerator to Scale Growth of Defense Tech Startups
Entrée Resources Wins Arbitration DecisionVitaGraft KidneyTM quantifies the amount of DNA fragments in transplant patients' blood that originate from the donor organ, a key biomarker for assessing graft health. This process is commonly referred to as donor-derived cell-free DNA (dd-cfDNA) testing and is widely used in clinical practice today. In this latest study, Oncocyte's proprietary diagnostic dd-cfDNA test using digital PCR was able to diagnose antibody-mediated rejection (AMR) in kidney transplant recipients nearly a year ahead of standard protocols 1 . "We are excited to see our dd-cfDNA technology demonstrate strong predictive value for AMR, supporting clinicians in identifying AMR in patients sooner, thereby enhancing the opportunity for better outcomes,” said Oncocyte Chief Science Officer Dr. Ekkehard Schuetz. "The trial's results further validate dd-cfDNA as a critical biomarker that can bridge diagnostic gaps for transplant patients.” For further context, de-novo donor specific antibody (dnDSA) is a routine biomarker used in kidney transplant management. The appearance of dnDSA in a patient -- that is, the patient is found to be dnDSA-positive (dnDSA+) -- signals an increased risk of AMR. This latest study shows that compared to standard of care, VitaGraft Kidney can significantly reduce the time to diagnosis of AMR in dnDSA+ patients. It is also the first randomized interventional study to validate any dd-cfDNA technology as a rule-in test for biopsy in a high-risk population. Catching AMR early, when kidney graft loss can be minimized, is becoming increasingly important as physicians explore the use of drugs, including the anti-CD38 drugs felzartamab and daratumumab, to manage rejection. Monitoring with VitaGraft in this high-risk patient population could support early intervention with these new therapeutic options. Once patients are on therapy, monitoring for therapeutic efficacy is also important to manage potential unwanted side effects. Publications using VitaGraft to monitor for efficacy for both aforementioned drugs can be found in the New England Journal of Medicine and Transplant International . In addition, earlier this year, Oncocyte signed an agreement with a European biotechnology company to be the provider of dd-cfDNA testing for a Phase II clinical trial for a separate therapeutic in AMR. Oncocyte expects to submit for claims expansion to its payor, MolDX 2 , to support the use of VitaGraft for these high-risk patients in the clinic. If granted, it would expand the use case beyond the current for-cause claim, opening significant new revenue opportunities. In sum, this clinical trial provides compelling evidence for dd-cfDNA monitoring as a tool for enhancing early intervention and improving outcomes for patients at increased risk of transplant rejection. Oncocyte scientists and inventors of the technology, Dr. Schuetz, Julia Beck and Kirsten Bornemann-Kolatzki, co-authored the study, which was initiated by researchers at Charité - Universitätsmedizin Berlin under the leadership of Prof. Klemens Budde. The study was published in Nephrology Dialysis Transplantation: Oxford Academic and may be found by accessing this link. Additional study details: Highlighting potential for improved patient outcomes, as well as implications for broader clinical applications and future therapies The interventional randomized trial, conducted between June 2021 and July 2023, involved 40 kidney transplant recipients with dnDSA, assessing longitudinal dd-cfDNA monitoring as a guiding tool for diagnostic biopsy compared to standard clinical practices. Oncocyte's proprietary dd-cfDNA technology was able to detect the onset of AMR significantly earlier in patients by guiding the indication for biopsy (median time from inclusion to diagnosis: 2.8 months) compared to the control group using standard of care (14.5 months). As noted above, this early intervention could offer a valuable advantage in transplant care by enabling prompt treatment before irreversible damage occurs. "This study underscores the impact of dd-cfDNA as a critical biomarker for early AMR detection, providing healthcare teams with timely data enabling them to initiate treatments sooner," said Dr. Aylin Akifova, first author from Charité. This study also suggests that dd-cfDNA monitoring could also be instrumental in identifying subclinical AMR-a silent condition that, if undiagnosed, can lead to significant graft damage. Additionally, the findings come at a crucial time, as mentioned above, as promising new treatments, including CD38-targeted therapies, are showing unprecedented efficacy in treating AMR. Early diagnosis with dd-cfDNA could provide the earliest window for intervention, offering an advantage for patients suffering from AMR, a disease with historically very limited treatment options. "We congratulate Charité's research teams on these compelling findings, which further underscore our mission to empower clinicians with tools for precision diagnostics while also democratizing access to novel molecular diagnostic testing to improve patient outcomes,” said Josh Riggs, CEO of Oncocyte. "We look forward to expanding the clinical applications of dd-cfDNA technology and supporting transplant communities worldwide with our innovative diagnostic solutions.” About Oncocyte Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft LiverTM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 [email protected] Forward-Looking Statements Any statements that are not historical fact (including but not limited to statements that contain words such as "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” "may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the expectation that Oncocyte will submit for claims expansion to MolDX to support the use of VitaGraft for high-risk patients in the clinic, which may expand the use case and open significant new revenue opportunities, the company's anticipated expansion of clinical applications of dd-cfDNA technology, the company's goal to support transplant communities worldwide with its innovative diagnostic solutions, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors” and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
ELDRED: 'View from the Foxhole' at museum SundayProtein Alternatives Market Growth Drivers, Latest Trends, Opportunities, Challenges, Recent Developments, Key Segments, Regional Insights, and Revenue Forecast 12-19-2024 11:42 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire MarketsandMarkets� Protein Alternatives Market by Source (Plant Protein, Microbial Protein, Insect Protein), Application (Food & Beverages, Animal Feed, Pet Food), Form, Nature, Production Process (Qualitative), & Region - Global Forecast to 2029 The global [ https://www.prnewswire.com/news-releases/protein-alternatives-market-worth-25-2-billion-by-2029--exclusive-report-by-marketsandmarkets-302186658.html ] is estimated at USD 15.7 billion in 2024; it is projected to grow at a CAGR of 9.9% to reach USD 25.2 billion by 2029. The protein alternatives market has experienced rapid growth and diversification in recent years, driven by increasing consumer demand for sustainable, health-conscious, and ethically produced food options. Key drivers of this market include rising concerns over the environmental impact of traditional animal agriculture, the health benefits associated with plant-based diets, and ethical considerations regarding animal welfare. Major segments within the protein alternatives market include plant-based proteins, insect-based proteins, and microbial proteins. Companies like Beyond Meat, Impossible Foods, and Oatly have become household names, reflected the mainstream acceptance and expanding consumer base for these products. Technological advancements and significant investments from both food industry giants and venture capitalists have further accelerated the development and accessibility of innovative protein alternatives. Image: https://www.marketsandmarkets.com/Images/alternative-protein-market-overview.webp [ https://www.globenewswire.com/en/news-release/2024/07/08/2909405/0/en/Protein-Alternatives-Market-is-Booming-and-Expected-to-Grow-25-2-billion-by-2029.html]: Increasing Demand for Alternate Protein The increasing global population underscores the necessity for alternative protein sources. Over the past decade, significant efforts have focused on developing proteins from non-traditional crops and livestock. This trend is particularly noticeable in Europe and North America, where consumer interest and investment in alternative proteins have surged. The conventional sources of animal protein like pork, beef, and chicken are projected to be insufficient to meet future demands, creating opportunities for the expansion of the insect protein market. In addition to proteins and fats, insects are valued for their rich mineral and vitamin content. Among younger demographics, particularly in sports nutrition, insect proteins, such as cricket flour, are gaining popularity and are being incorporated into various nutritious food products. For instance, startups like Next Step Foods in the UK produce cricket protein bars like "Yuana" available in multiple flavors. The shift to alternative proteins also promises environmental benefits, notably in reducing greenhouse gas emissions compared to traditional meat production, as highlighted by the World Economic Forum in 2019. Moreover, adopting alternative proteins addresses diet-related health concerns in developing countries and promotes healthier lifestyles in developed regions such as North America and Europe. These areas have already embraced alternative protein sources such as edible insects, plant-based meat, plant protein ingredients, and cultured meat. Industry experts predict significant market growth potential for these products, with cultured and plant-based meat alone expected to see over 40% growth in the coming years. In 2022, a study funded by the European Regional Development Fund revealed that 22% of UK consumers preferred alternative protein sources over meat, with the younger demographic showing an even higher preference exceeding 25%. These trends underscore the growing market opportunities in the insect protein sector. [ https://www.linkedin.com/pulse/protein-alternatives-market-size-share-industry-overview-edward-scott-oaknf/]: Changes in consumer lifestyles The global population's expansion is placing heightened strain on limited resources, with escalating energy prices and raw material expenses impacting food costs, particularly affecting lower-income demographics. Additionally, the strain on food resources is being intensified by water scarcity, notably prevalent across Africa and Northern Asia. Within the Asia Pacific region, there exists a cost advantage in terms of both production and processing, fostering high demand and offering favorable conditions for dairy alternative suppliers and manufacturers to target this market. As lifestyles evolve rapidly, there's a noticeable shift towards more nutritious and health-conscious food options. The distinction between fast food and junk food is anticipated to grow, with consumers increasingly seeking quick yet wholesome alternatives. Recognizing naturally rich nutritional products presents a significant opportunity for suppliers and manufacturers to meet evolving consumer preferences. Furthermore, the rise in disposable incomes is driving demand for convenient, healthy, and highly nutritious products across Asia Pacific nations. Emerging economies within the region present substantial opportunities for growth within the protein alternatives market. Plant protein is estimated to be the fastest source segment in the protein alternatives market during the forecasted period of 2024-2029. Plant protein has rapidly emerged as the frontrunner in the protein alternatives market, prized for its speed of adoption and nutritional benefits. With consumers increasingly focused on health, sustainability, and ethical considerations, plant-based proteins offer a compelling solution. Unlike traditional animal-derived proteins, which often come with environmental concerns and ethical debates, plant proteins are generally more sustainable to produce and consume. One of the key reasons for the swift ascent of plant protein in the market is its versatility. Manufacturers can extract protein from a wide array of plant sources, such as peas, soybeans, hemp, and even algae, offering a diverse range of products that cater to different dietary preferences and needs. This diversity fuels innovation, leading to products that not only match but sometimes surpass their animal-based counterparts in taste, texture, and nutritional profile. Furthermore, plant protein's rapid digestion and absorption rate make it highly appealing to athletes and health-conscious individuals seeking efficient protein sources for muscle recovery and overall wellness. As research continues to highlight the health benefits of plant-based diets, including reduced risks of chronic diseases, the popularity of plant protein is expected to continue its meteoric rise in the protein alternatives market. Make an Inquiry to Address your Specific Business Needs: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=233726079 The North American region is projected to dominate the protein alternatives market. North America stands as the dominant region in the protein alternatives market, owing to its robust infrastructure, technological advancements, and growing consumer demand for sustainable food sources. This leadership is underscored by strategic developments such as in January 2022 ADM's (US) collaboration with Innova Feed (France), aimed at supplying insect protein for ADM's pet food division while leveraging waste heat and water resources effectively. This partnership not only enhances ADM's product offerings but also reinforces sustainability initiatives in the pet food industry. Similarly, In May 2021, Cargill's (US) strategic partnership with InnovaFeed (France) focuses on supplying insect feed for aquaculture and integrating insect oil into pig feed, addressing the increasing need for innovative protein sources in animal nutrition. These collaborations highlight North America's pivotal role in advancing protein alternatives through strategic alliances that promote sustainability and technological innovation in the food and feed sectors. [ https://www.marketsandmarkets.com/ResearchInsight/alternative-protein-market.asp ] Key Market Players in this include Tate & Lyle PLC (London), Kerry Group PLC (Ireland), DSM Firmenich (Switzerland, ADM (US), Cargill Incorporated (US), International Flavors & Fragrances Inc. (US), Ingredion (US), Roquette Freres (France), Wilmar International Ltd. (Singapore), Glanbia plc (Ireland), AGT Food and Ingredients (Canada), Tate & Lyle (UK), PURIS (US), Ynsect (France), Global bugs (Thailand), and Innovafeed (France). ADM (US) ADM, known formally as the Archer Daniels Midland Company, is a significant entity in multiple industries, including food ingredients, animal feed, biofuels, and industrial chemicals. With a rich history exceeding a century, ADM has developed a diverse portfolio that spans the entire agricultural value chain. The company excels in sourcing, processing, and distributing agricultural commodities globally, particularly grains and oilseeds. ADM's extensive network of facilities and logistics infrastructure enables efficient connections between farmers and customers worldwide. In the nutrition sector, ADM is recognized as a global leader, especially in plant protein innovation. With 75 years of expertise, it is one of the world's largest soybean processors. ADM operates through four main segments: Ag Services and Oilseeds, Carbohydrate Solutions, Nutrition, and Other Business. The company offers a wide range of protein alternatives which are plant-based, suitable for various food applications, from bakery goods to meat alternatives. ADM's global presence spans North America, South America, Europe, Asia Pacific, and Africa, supported by a comprehensive supply chain network that includes crop procurement locations, manufacturing facilities, innovation centers, and transportation networks. Cargill, Incorporated (US) Founded in 1865, Cargill, Incorporated has grown to become one of the largest privately held companies in the United States, with a robust global footprint. The company provides a wide range of products, including food ingredients, bio-industrial goods, animal nutrition solutions, protein, salt, and financial services. Cargill operates through 75 business units organized into four primary segments: agriculture, food, financial services, and industrial products. Cargill's plant-based protein offerings are integral to various food products such as bread, snacks, confectionery, and culinary ingredients. The company maintains strategically located research and development facilities in Europe and North America, and its operations span across Africa, Europe, Asia, Latin America, North America, and the Middle East. Cargill operates in 70 countries through its subsidiaries and affiliates, with notable subsidiaries including Cargill Meat Solutions (US), Cargill Enterprises Inc. (Russia), and Cargill Asia Pacific Holdings Pte Limited (Singapore). In addition to plant-based proteins, Cargill also offers a range of protein alternatives that include both plant-based and microbial-based options. These alternative proteins are increasingly incorporated into a variety of food products to meet the growing demand for sustainable and nutritious food sources. By leveraging its extensive global network and advanced research capabilities, Cargill is at the forefront of innovation in the alternative protein market, ensuring that their products not only meet but exceed consumer expectations for taste, texture, and nutritional value. [ https://www.marketsandmarkets.com/Market-Reports/alternative-protein-market-233726079.html]: In January 2024, Ynsect became the first company authorized to commercialize mealworm proteins for dog food in the United States as of January 24, 2024. This milestone allows Ynsect to expand its sustainable insect protein offerings into the US pet food market, meeting the rising consumer demand for eco-friendly pet nutrition. This authorization is expected to enhance Ynsect's market presence and support the trend of using insect-based proteins in pet food. In February 2024, Roquette expanded its Nutralys plant protein line by launching four new pea protein products, encompassing isolates, hydrolysates, and textured variants. These versatile pea proteins are designed to address formulation challenges in plant-based foods and high-protein nutritional products. They pave the way for innovation in various items, including nutritional bars, protein beverages, and plant-based meat and dairy alternatives. Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=233726079 About MarketsandMarkets Trademark MarketsandMarketsTM has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets Trademark is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore Trademark (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. Media Contact Company Name: MarketsandMarkets Trademark Research Private Ltd. Contact Person: Mr. Rohan Salgarkar Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=protein-alternatives-market-growth-drivers-latest-trends-opportunities-challenges-recent-developments-key-segments-regional-insights-and-revenue-forecast ] Phone: 18886006441 Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 City: Florida State: Florida Country: United States Website: https://www.marketsandmarkets.com/Market-Reports/alternative-protein-market-233726079.html This release was published on openPR.Environmental advocates are cautiously optimistic after the Supreme Court left California’s nation-leading auto emissions standards in place — at least for the moment. The Supreme Court declined to hear a challenge from Ohio and 16 other conservative states that aimed to strip California of its authority to adopt vehicle emissions standards stricter than federal benchmarks. However, days earlier, justices announced they will decide whether red-state fuel producers have legal standing to sue the U.S. Environmental Protection Agency for alleged financial losses caused by California’s stringent fuel economy standards and electric vehicle mandate. State policymakers and environmental advocates view the Supreme Court’s decision to leave California’s regulatory powers intact as a triumph. But, as an adversarial presidential administration is poised to take office, experts say they anticipate a flurry of legal objections over nearly all forthcoming California clean air policies. “The Supreme Court was right to turn away this radical request by Republican-led states to upend decades of law letting California cut pollution and clean our air,” said Daniel Villaseñor, a spokesperson for Gov. Gavin Newsom. “California’s authority was codified in the Clean Air Act by none other than Republican Richard Nixon, who recognized that California should continue serving as a lab for innovation to show the nation what’s possible with smart policy.” The battle to alleviate air pollution and reduce planet-warming gases will be waged largely in the courts over the next four years, according to experts. And the legal strategy, they say, will need to focus on defending California’s aggressive clean air rules as much as it will be about ushering in new regulation. “It’s good news, at least in the short term,” said Joe Lyou, president of California-based nonprofit the Coalition for Clean Air. “Everyone’s concerned about what’s going to happen in the long term. But this is a good start to what will undoubtedly be a long, long battle over clean air over the next four years. A lot of it is going to be up to the lawyers.” Several industry groups have already filed litigation to contest California’s rules, including a ban on new sales of gasoline vehicles in 2035. Last week, when the Supreme Court announced it would review a legal challenge over how California regulations affected fuel producers, it signaled its willingness to consider objections to California’s vehicle emission rules. However, the justices won’t be weighing the merits of the case, only whether the fuel companies have the right to sue. The District of Columbia Court of Appeals had previously ruled the lawsuit invalid, in part, because fuel producers are challenging California emission standards adopted in 2012. Because car manufacturers already comply with the standard, there is no feasible remedy for their claims, experts say. Another part of the fuel producers’ argument is that the Clean Air Act only grants California the ability to regulate conventional vehicle pollution for clean air — such as smog-forming nitrogen oxides — not planet-warming gases such as CO2 to address global warming. “Their argument is this authority was given to California because they have really bad smog problems, not because of climate change,” said Ann Carlson, the founding director of the Emmett Institute on Climate Change & the Environment at UCLA. “And therefore, they shouldn’t be able to regulate greenhouse gases under this special power they have.” But many environmental advocates say that argument may be moot. California air regulators have long maintained that air quality issues in major California cities — including smoggy Los Angeles — are so severe that electric vehicles are necessary to meet pollution standards. Air pollution and greenhouse gas emissions go hand in hand, they say. “You have a technology, in these zero emission vehicles, that can reduce the full spectrum of pollution,” said Alice Henderson, lead counsel for transportation and clean air policy at the Environmental Defense Fund, an organization that has helped defend California rules. “And it is sort of laughable to think that these air agencies should be forced to ignore that technology.” But the fight to enshrine clean air rules is not just legal sparring. For Lyou, it’s about the health consequences of inhaling air pollution. According to the California Air Resources Board, air pollution contributes to roughly 5,000 premature deaths each year in Southern California. “It really comes down to whether people are going to have asthma attacks, whether people die prematurely or whether people have heart attacks,” Lyou said. “These are lives at stake.”Irish premier Simon Harris has said Fine Gael will gain seats in the General Election despite a further fragmentation of Irish politics. Fine Gael won 35 seats in the 2020 election, but 18 of those TDs did not seek re-election in Friday’s poll. An exit poll puts the party’s support at 21%, a fraction of a percentage behind the main opposition party Sinn Fein. Mr Harris, the outgoing Taoiseach, was elected with 16,869 first preference votes, well above the quota. He celebrated with his wife Caoimhe, his parents Bart and Mary, his sister Gemma and his political team at the count centre in Greystones, Co Wicklow. Ahead of his re-election, Mr Harris told reporters he was “cautiously optimistic” about the election result and said it was “clear that my party will gain seats”. “It’s also clear that Fine Gael will top the poll in at least 10 constituencies, many more than we did the last time, that we will gain seats in constituencies where we haven’t had seats in many years, like Tipperary South and Waterford, and that we will add second seats in other constituencies as well,” he said. “I think the people of Ireland have now spoken. We now have to work out exactly what they have said, and that is going to take a little bit of time.” In one of the five consecutive broadcast media rounds he did from the Greystones count centre, he said there were a lot of areas where there were “straight shoot-outs” between Fianna Fail and Fine Gael for final seats. He described the Sinn Fein vote as “pretty significantly down”, the Fianna Fail vote as “marginally down” and the Fine Gael vote as “static” compared with its 2020 vote. He said it was “a very close, a very competitive election” and that “we haven’t seen a Sinn Fein surge or anything like it”. He said: “It was predicted by many that I would become the Taoiseach for a brief period of time, take over from Leo Varadkar, and then have to rebuild my party from the opposition benches as Sinn Fein led a government. “We don’t know what’s going to happen on government formation yet, but that is now looking less likely than it was.” He acknowledged that it was “a very difficult day” for the Green Party and paid tribute to their work in the coalition government, alongside his party and Fianna Fail. “Definitely, politics in Ireland has gotten much more fragmented,” he said. Fine Gael minister Helen McEntee said that her party’s campaign had been “positive”. “The feeling on the doors was very much that people were relatively happy with the government,” she said on RTE Radio. “It will come down to the last seats and it will come down to transfers,” she said of the final result, adding that Fianna Fail and Fine Gael were performing better than the exit poll estimated.
None
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms